title: Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
abstract: OBJECTIVE
  To review the efficacy, safety, and dose of recombinant activated factor VII in off-label management of refractory bleeding in pediatric patients with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass.
  
  
  METHODS
  A retrospective database analysis with medical records review.
  
  
  METHODS
  A single research hospital.
  
  
  METHODS
  Ninety pediatric patients with uncontrolled postoperative hemorrhage after cardiac surgery with cardiopulmonary bypass for congenital heart disease.
  
  
  METHODS
  Intravenous recombinant activated factor VII treatment according to institutional treatment protocol.
  
  
  RESULTS
  The recombinant activated factor VII treatment was effective in reducing bleeding in 78 pediatric patients. The 12 patients who failed to respond had surgical sources of bleeding. The mean blood loss decreased from 51.04 mL/kg/2 h to 7.8 mL/kg/2 h (p < 0.001) in neonates, from 40.2 mL/kg/2 h to 7.7 mL/kg/2 h (p < 0.001) in infants, and from 29.1 mL/kg/2 h to 4.0 mL/kg/2 h in children (p < 0.001). The mean (standard deviation) total recombinant activated factor VII doses required to achieve hemostasis were 131.7 (69.8) μg/kg in neonates, 104.6 (36.0) μg/kg in infants, and 44.6 (15.3) μg/kg in children aged 1 to ≤18 years. There was no evidence of thrombosis in the first 24 hours after the administration of recombinant activated factor VII.
  
  
  CONCLUSIONS
  Recombinant activated factor VII treatment reduced blood loss and transfusion requirements and prevented re-exploration in the majority (83.8%) of pediatric cardiac surgery patients. High doses were required to discontinue bleeding promptly in neonates, the majority of whom had hypoplastic left-heart syndrome. No treatment-related thrombotic events were observed.
authors.affiliation: Department of Anesthesiology and Intensive Care, Polish Mother Memorial Hospital Research Institute, Lodz, Poland. mpokorska@o2.pl
authors.forename: Magdalena
authors.initials: M
authors.lastname: Pychyńska-Pokorska
authors.forename: Izabela
authors.initials: I
authors.lastname: Pągowska-Klimek
authors.forename: Wojciech
authors.initials: W
authors.lastname: Krajewski
authors.forename: Jacek Jan
authors.initials: JJ
authors.lastname: Moll
mesh_terms: D000293:Adolescent; D000375:Aging / Q000502:physiology; D000925:Anticoagulants / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000628:therapy; D016063:Blood Loss, Surgical; D001803:Blood Transfusion / Q000706:statistics & numerical data; D006348:Cardiac Surgical Procedures / Q000379:methods*; D002315:Cardiopulmonary Bypass / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D017548:Echocardiography, Transesophageal; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery; D006490:Hemostatics; D006494:Heparin Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D056687:Off-Label Use; D010314:Partial Thromboplastin Time; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D011479:Protamines / Q000627:therapeutic use; D011517:Prothrombin Time; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D013927:Thrombosis / Q000175:diagnosis / Q000628:therapy
chemical_list: D000925:Anticoagulants; D006490:Hemostatics; D006494:Heparin Antagonists; D011479:Protamines; D011994:Recombinant Proteins; D015942:Factor VIIa